Evidence map›Paper›PMID 31072919›Full record

Trial reportBioscience reports2019

Activin A: a novel urinary biomarker of renal impairment in multiple myeloma.

Hirono Iriuchishima, Akito Maeshima, Shunsuke Takahashi, Takuma Ishizaki, Akihiko Yokohama, Norifumi Tsukamoto, Takayuki Saitoh, Hirokazu Murakami, Hiroshi Handa

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Bioscience reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Clinical Proteomics of Biofluids in Haematological Malignancies.International journal of molecular sciences · 2021
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Hirono IriuchishimaDepartment of Hematology, Gunma University Graduate School of Medicine, Gunma, Japan iriuchishima.h@gmail.com amaesima@jichi.ac.jp.ORCID 0000-0002-6970-9881
Akito MaeshimaDivision of Nephrology, Department of Internal Medicine, Jichi Medical University, Tochigi, Japan iriuchishima.h@gmail.com amaesima@jichi.ac.jp.
Shunsuke TakahashiDepartment of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, Gunma, Japan.
Takuma IshizakiDepartment of Hematology, Gunma University Graduate School of Medicine, Gunma, Japan.
Akihiko YokohamaDepartment of Blood Transfusion, Gunma University Hospital, Gunma, Japan.
Norifumi TsukamotoDepartment of Oncology Center, Gunma University Hospital, Gunma, Japan.
Takayuki SaitohDepartment of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Gunma, Japan.
Hirokazu MurakamiDepartment of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Gunma, Japan.
Hiroshi HandaDepartment of Hematology, Gunma University Graduate School of Medicine, Gunma, Japan.ORCID 0000-0003-3753-9862
Gunma University · JPGunma University Hospital · JPJichi Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal impairment (RI) is a common complication of multiple myeloma (MM) that significantly affects treatment efficacy and mortality. However, no useful biomarkers for early detection of renal damage in MM exist. Reports indicate that activin A, a multifunctional cytokine of the TGF-β superfamily, is involved in the development and progression of various kidney diseases. In the present study, we measured urinary activin A levels in patients with newly diagnosed MM (NDMM) (

Indexed as

ActivinsAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansKidney DiseasesMaleMiddle AgedMultiple Myelomaactivin AActivinsBiomarkers, Tumoractivin Abiomarkermultiple myelomarenal impairment

Identifiers

PMID31072919
PMCPMC6542761
OpenAlexW2944075099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.